182 related articles for article (PubMed ID: 32873863)
1. HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study.
Dundr P; Bártů M; Hojný J; Michálková R; Hájková N; Stružinská I; Krkavcová E; Hadravský L; Kleissnerová L; Kopejsková J; Hiep BQ; Němejcová K; Jakša R; Čapoun O; Řezáč J; Jirsová K; Franková V
Sci Rep; 2020 Sep; 10(1):14365. PubMed ID: 32873863
[TBL] [Abstract][Full Text] [Related]
2. HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer.
Wang J; He C; Gao P; Wang S; Lv R; Zhou H; Zhou Q; Zhang K; Sun J; Fan C; Ding G; Lan F
Oncogene; 2020 Feb; 39(6):1335-1346. PubMed ID: 31636385
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122 cases of high-grade serous ovarian carcinoma.
Němejcová K; Bártů M; Hojný J; Hájková N; Michálková R; Krkavcová E; Stružinská I; Bui HQ; Dundr P; Cibula D; Jirsová K
Oncol Lett; 2021 Mar; 21(3):185. PubMed ID: 33574924
[TBL] [Abstract][Full Text] [Related]
4. HNF1B inhibits cell proliferation via repression of SMAD6 expression in prostate cancer.
Lu W; Sun J; Zhou H; Wang F; Zhao C; Li K; Fan C; Ding G; Wang J
J Cell Mol Med; 2020 Dec; 24(24):14539-14548. PubMed ID: 33174391
[TBL] [Abstract][Full Text] [Related]
5. HNF1B expression regulates ECI2 gene expression, potentially serving a role in prostate cancer progression.
Dan C; Zhang H; Zeng W; Huang L; Gong X; Li H; Yang E; Wang L; Yao Q
Oncol Lett; 2019 Jan; 17(1):1094-1100. PubMed ID: 30655870
[TBL] [Abstract][Full Text] [Related]
6. Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer.
Harries LW; Perry JR; McCullagh P; Crundwell M
BMC Cancer; 2010 Jun; 10():315. PubMed ID: 20569440
[TBL] [Abstract][Full Text] [Related]
7. HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.
Ross-Adams H; Ball S; Lawrenson K; Halim S; Russell R; Wells C; Strand SH; Ørntoft TF; Larson M; Armasu S; Massie CE; Asim M; Mortensen MM; Borre M; Woodfine K; Warren AY; Lamb AD; Kay J; Whitaker H; Ramos-Montoya A; Murrell A; Sørensen KD; Fridley BL; Goode EL; Gayther SA; Masters J; Neal DE; Mills IG
Oncotarget; 2016 Nov; 7(46):74734-74746. PubMed ID: 27732966
[TBL] [Abstract][Full Text] [Related]
8. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
9. [EZH2 expression in human prostate cancer and its clinicopathologic significance].
Li J; Fan QH; Fan XS; Zhou W; Qiu Y; Qiu L
Zhonghua Nan Ke Xue; 2010 Feb; 16(2):123-8. PubMed ID: 20369694
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
11. Lipid degradation promotes prostate cancer cell survival.
Itkonen HM; Brown M; Urbanucci A; Tredwell G; Ho Lau C; Barfeld S; Hart C; Guldvik IJ; Takhar M; Heemers HV; Erho N; Bloch K; Davicioni E; Derua R; Waelkens E; Mohler JL; Clarke N; Swinnen JV; Keun HC; Rekvig OP; Mills IG
Oncotarget; 2017 Jun; 8(24):38264-38275. PubMed ID: 28415728
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing Approach in Methylation Analysis of HNF1B and GATA4 Genes: Searching for Biomarkers in Ovarian Cancer.
Bubancova I; Kovarikova H; Laco J; Ruszova E; Dvorak O; Palicka V; Chmelarova M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241454
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
14. Expression, Epigenetic, and Genetic Changes of HNF1B in Colorectal Lesions: an Analysis of 145 Cases.
Bártů M; Hojný J; Hájková N; Michálková R; Krkavcová E; Simon K; Frýba V; Stružinská I; Němejcová K; Dundr P
Pathol Oncol Res; 2020 Oct; 26(4):2337-2350. PubMed ID: 32488808
[TBL] [Abstract][Full Text] [Related]
15. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract][Full Text] [Related]
16. The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters.
Ngollo M; Lebert A; Dagdemir A; Judes G; Karsli-Ceppioglu S; Daures M; Kemeny JL; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon D
BMC Cancer; 2014 Dec; 14():994. PubMed ID: 25535400
[TBL] [Abstract][Full Text] [Related]
17. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
18. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
20. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
